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Abstract
Background: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, has been clinically
applied for the treatment of a variety of tumors with EGFR overexpression. A phase II clinical study of erlotinib
(NCIC IND-148) for recurrent or metastatic endometrial carcinoma (EC) resulted in an unfavorable result. However,
in that study, the expression levels of EGFR were not accurately analyzed. Thus, the aim of this study was to re-examine
the efficacy of erlotinib in EC cells by utilizing in vitro and in vivo models.
Methods: Tissue samples obtained from patients histologically diagnosed with EC of the uterine corpus were
subjected to immunohistochemistry and RT-PCR to determine the protein and mRNA expression levels of EGFR.
Western blot and WST-1 assays of EGFR siRNA-transfected HEC-1A, KLE, and Ishikawa cells were used to evaluate the
efficacy of erlotinib in tumor cell lines expressing different EGFR levels. Furthermore, HEC-1A and Ishikawa cells were
implanted into athymic mice treated with either erlotinib or trastuzumab.
Results: At our institution, 20.9 % of endometrial cancer patients with low grade endometrioid histology have been
diagnosed as stage III and IV. Immunohistochemical analysis and RT-PCR revealed the presence of significant EGFR and
EGFR mRNA expression in low-grade endometrioid carcinoma in comparison with high-grade endometrioid carcinoma.
In vitro study, WST-1 assay and Western blot analysis revealed that EGFR expression levels were correlated with tumor
cell viability. Erlotinib reduced the proliferation of HEC-1A expressing high levels of EGFR, while trastuzumab showed
similar effect in Ishikawa cells dominantly expressing human epidermal growth factor receptor type2 (HER2). In vivo
erlotinib decreased tumor growth in mice xenografted with HEC-1A cells, whereas this tumor-growth inhibition was
not observed in trastuzumab-treated mice xenografted with Ishikawa cell.
Conclusions: EGF contributed to tumor proliferation in EC cell lines along with EGFR expression in vitro. Erlotinib also
demonstrated anti-tumor effects in xenograft mice models. Our results suggest that erlotinib continues to have clinical
usefulness in specific cases, after taking into consideration the EGFR expression levels.
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Background
Endometrial carcinoma (EC) is one of the most common
gynecological malignant tumors in Japan; over 8000
women were diagnosed with it in 2012. There are two
subtypes of endometrial carcinoma according to the
clinico-pathological characteristics: type I EC and type
II EC [1, 2]. Recent studies on gene signature in EC
cells have reported numerous genetic disorders that
initiate carcinogenesis: for instance, PTEN, which regu-
lates normal cell function, is highly mutated in type I EC,
whereas p53, which prevents genome mutation, is altered
by up to 80–90 % in type II EC [3].
Type I EC accounts for about 80 % of EC, and is gener-
ally associated with better prognosis than type II EC since
it is composed of low grade endometrioid histology with
less aggressive characteristics and favorable prognosis [3].
However, the number of patients with advanced stage or
recurrent low-grade tumors might not be negligible since
type I EC comprises about 80 % of the newly diagnosed
EC in Western Europe, North America, and Japan [3, 4].
After staging surgery, adjuvant therapy is considered
based on the pathological risk factors, such as tumor
grade, histological type, myometrial invasion, positive mar-
gin, lymphovascular space invasion, and positive node sta-
tus [5]. Radiotherapy has proved to reduce the risk of local
recurrence, but no randomized study has shown benefit
for overall survival [6, 7]. In the last decades, there has
been emerging evidence suggesting that systemic cytotoxic
chemotherapy may have favorable prognosis in advanced
EC [8, 9]. Taxanes, platinum agents, and anthracyclines
have been utilized in advanced and recurrent EC patients,
with response rates to these drugs ranging from 33 to
57 % [8, 10–14].
Cytotoxic cancer therapy induces apoptosis in cancer
cells by inhibiting microtubule function, protein function,
or DNA synthesis. In contrast, molecular-targeted therapy
is designed to interfere with specific molecules involved in
cancer cell proliferation and metastasis. Recently, a better
understanding of the molecular and genetic characteristics
of EC has promoted clinical research that targets angio-
genesis and cellular signaling pathways involved in cancer
development and progression. Epidermal growth factor
receptor (EGFR) has been shown to be overexpressed
in many human cancers, including lung [15, 16], central
nervous system [17], head and neck [18], bladder [19],
pancreas [20], and breast [21]; and it correlates with
poor prognosis [22]. EGFR expression has been found
to be associated with patient outcomes in 43–67 % of
EC tissue samples [23–25] and different profiles in low
and high grade EC [26]. Furthermore, some studies
have reported that the EGFR family plays an important
role in the development of EC [27, 28]. Collectively, inhib-
ition of EGFR function can be a clinical benefit. Targeted
therapy against the signaling system of the tyrosine kinase
family could be beneficial for patients with type II EC
[29, 30]. Those reports found that the expression of EGFR
and human epidermal growth factor receptor type2
(HER2) in type II EC was 30.5 and 16.5 %, respectively,
whereas it was 51.5 and 2 % in well (Grade 1, G1) and
moderately (G2) differentiated endometrioid cancer, re-
spectively. However, there have been no promising therap-
ies, including small molecule tyrosine kinase inhibitors or
anti-EGFR monoclonal antibodies, for antagonizing EGFR
functions [31, 32]. Thus, in this study, we aimed to evalu-
ate whether targeting the EGFR tyrosine kinase may have
a therapeutic effect against EC, by accurately assessing the
expression levels of EGFR in cancer cells.
Methods
Reagents
Erlotinib (Abcam, Tokyo, Japan) was dissolved in DMSO,
and pertuzumab (Tyugai, Tokyo, Japan) was dissolved in
distilled water for the in vitro and in vivo studies. Epider-
mal growth factor (EGF) (Invitrogen, Carlsbad, CA, USA)
was dissolved in phosphate buffered saline (PBS) (stock
solution: 20 ng/mL).
DMEM (without phenol red) and gentamicin sulfate
(Geneticin) were purchased from Invitrogen (Carlsbad, CA,
USA). DMEM/Ham’s nutrient mixture F-12 (1:1, vol/vol)
(without phenol red) was purchased from Sigma-Aldrich
(St. Louis, MO, USA).
Cell culture and culture condition
Ishikawa cells were purchased from Japanese Collection of
Research Bioresources (JCRB) cell bank (Tokyo, Japan).
HEC293, HEC-1A, and KLE cells were purchased from
American Type Culture Collection (Manassas, VA, USA).
All the cells used for the experiments were between the
5th and 20th passages.
HEC293 and Ishikawa cells were maintained in DMEM
supplemented with 10 % charcoal fetal bovine serum
(FBS) and 50 μg/μL gentamicin sulfate. HEC-1A cells were
maintained in McCoy’s 5A medium supplemented with
10 % charcoal FBS. KLE cells were maintained in DMEM/
nutrient mix F-12 Ham’s supplemented with 5 % charcoal
FBS. All media used were phenol red free. Cells were incu-
bated at 37 °C in a humidified atmosphere containing 5 %
CO2. All cells were harvested using trypsin/EDTA when
confluence was less than 80 %. All cells were used all
experiments when cell concentration was 60–70 %.
Tissues and patient cohort
Resected tissue samples (only hysterectomy samples
without neoadjuvant treatment) were obtained from 51
endometrioid adenocarcinoma patients of Asian descent
between May 2007 and March 2011 from Gunma Univer-
sity Hospital. All patients had been identified as uterine
corpus endometrioid adenocarcinoma carriers on the basis
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of gynecologic and pathological reports. Staging was
defined according to the International Federation of
Obstetricians and Gynecologists (FIGO) Surgical staging
system [33]. The histological grade classification was ac-
cording to the World Health Organization classification
and FIGO [34]. This study was approved by the Insti-
tutional Review Board of Gunma University (Permit
Number: 12–49) and conducted according to the ethical
guidelines of Gunma University. Tissue specimens were
handled according to the local ethics committee guidelines.
Written informed consent was obtained from all patients
enrolled in the study.
Immunohistochemistry
Formalin fixed samples were embedded in paraffin and
sectioned and dried; then, they were deparaffinized and
rehydrated. The sections were immunostained using
DAKO ENVISION+ KIT/HRP (DAKO, Carpentaria,
CA, USA) and Histofine SAB-PO kit (Nichirei, Tokyo,
Japan) according to manufacturers’ protocols. Rabbit
monoclonal anti-EGFR antibody (diluted 1:100, DAKO,
Carpentaria, CA, USA) and mouse monoclonal anti-HER-2
antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) were used for immunohistochemistry (IHC) to deter-
mine EGFR and HER-2 expression levels. Two independent
pathologists who were blinded to the clinical information
assessed EGFR and HER-2 expression. The inter-observer
disagreements (kappa statistics: 0.91) were reviewed a
second time, followed by a conclusive decision by both
pathologists. A positive result was defined as cell mem-
brane staining of 50 % or above, independently of intensity.
Western blotting
Twenty-four hours before starting the analysis, all cells
were changed to a free- FBS medium. For the analysis of
phosphorylated extracellular signal-regulated kinases (ERK)
1/2, cells were treated with EGF (range from 1 pg/mL to
1 ng/mL) for 10 min, washed twice with cold PBS, and in-
cubated on ice with RIPA buffer (pH 7.4, supplemented
with protease inhibitors, 200 mM NaF, 200 mM sodium
orthovanadate) for 30 min. Lysates were aspirated and
centrifuged at 15,000 rpm for 10 min at 4 °C. The protein
concentration was measured in the collected supernatant.
Frozen patient samples were homogenized and lysed in
RIPA buffer. Protein samples (10–20 mg) were diluted in
equal volume sample buffer (pH 6.8, 4 % SDS, 10 % 2-
mercaptoethanol, 20 % glycerol, 0.004 % bromophenol blue,
0.125 M Tris–HCl) and incubated for 30 min at 25 °C.
Protein samples were loaded on a 12 % polyacrylamide/
bisacrylamide SDS-PAGE gel and transferred onto a PVDF
membrane (BIO-RAD, Hercules, CA, USA). Membranes
were blocked with 5 % BSA or 5 % skim milk in TBST
(100 mM Tris, 0.9 % NaCl, 0.1 % Tween-20, pH 7.4) for
1 h at room temperature. Membranes were incubated
overnight at 4 °C with the primary antibody (phosphor-
ERK 1/2 at 1:2000, total-ERK at 1:1000, EGFR at 1:1500,
rabbit anti-human HER-2 at 1:1000 [Cell Signaling Tech-
nology, MA, USA], and mouse anti-human beta-actin at
1:3000 [Sigma-Aldrich]). After incubation, the membranes
were washed 5 times with TBST and incubated with the
appropriate secondary antibody conjugated to horseradish
peroxidase (anti-rabbit or mouse at 1:40000, BIO-RAD)
for 1 h at room temperature. After washing 5 more times
with TBST, the membranes were incubated with Immobi-
lon Western Detection reagent (Millipore, Billerica, MA,
USA) for 5 min and detected by an Image Quant Imager
(GE Healthcare Bio Science). The expression levels of
phosphorylated ERK were quantified by scanning the
digital image and digitized data were analyzed with the
Image J (NIH, USA).
RNA isolation and quantitative RT-PCR
RNA was extracted from the endometrial cancer cell lines
and primary resected endometrioid adenocarcinoma tissue
samples. Total cellular and tissue RNA were extracted
using Isogen (WAKO, Osaka, Japan) and 2 μg total RNA
was treated with DNase I (Isogen, De Meern, Netherlands)
according to manufacturer’s protocol. RNA was reverse
transcribed using SuperScript III transcriptase (Invitrogen)
with random primers (Invitrogen). The samples were in-
cubated with RNAse at 37 °C to remove RNA, and were
diluted with distilled water for a final volume of 100 μL.
Each quantitative PCR consisted of 5 μL of cDNA tem-
plate, 12.5 μL SYBR Green real-time PCR master mix
(Toyobo, Osaka, Japan), 0.2 μL forward and reverse
primers (50 μM), and 7.1 μL distilled water. The sequences
for the forward and reverse primers are as follows: human
EGFR: 5’ –GGAGAACTGCCAGAAACTGACC- 3’ and
5’ –GCCTGCAGCACACTGGTTG- 3’; human HER-2:
5’ –ATCTGGCGCTTTTGGCACAG- 3’ and 5’ –CACCA
GCCATCACGTATGCT- 3’; human GAPDH: 5’ -AATTC
CATGGCACCGTCAAG- 3’ and 5’ –GGTGAAGACGCC
AGTGGACT- 3’. The reactions were carried out in an ABI
PRISM 7000 sequence detection system (Applied Biosys-
tems, Foster City, CA, USA) for 40 cycles (95 °C for 15 s,
60 °C for 1 min) after 1 min initial incubation at 95 °C. The
fold change in the expression levels of each gene was calcu-
lated using the standard curve method, with GAPDH as an
internal control.
siRNA transfection
SiRNA against human EGFR (EGFR siRNA) or HER-2
(HER-2 siRNA), and siRNA for negative control (control
siRNA) were obtained from Applied Biosystems. All cell
lines were plated for 24 h to approximately 50 % con-
fluence, and were transfected with 10 nM siRNA using
Lipofectamine RNAiMAX (Ambion, Grand Island, NY,
USA). The transfected cells were subjected to western
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Table 1 Characteristics of surgical cancer patients
Well differentiated Mediate differentiated Poorly differentiated P value
(G1) (n = 4) (G2) (n = 17) (G3) (n = 10)
Age† 57 (50–63) 59 (56–66) 58 (52–61) ns
BMI† 22.2 (20.0–28.6) 23.4 (20.3–25.0) 21.4 (20.7–23.6) ns
FIGO Surgical Stage ns
I 16 (66.7 %) 10 (58.8 %) 5 (50.0 %)
II 3 (12.5 %) 1 (5.9 %) 0 (0.0 %)
III 4 (16.7 %) 6 (35.3 %) 3 (30.0 %)
IV 1 (4.2 %) 0 (0 %) 2 (20.0 %)
†Median (Interquartile Range). FIGO International Federation of Gynecology and Obstetrics
Fig. 1 Detection of EGFR and HER-2 proteins in endometrial adenocarcinoma (surgically resected endometrioid cancer sample). a We used tissue
samples of well differentiated (G1), moderately differentiated (G2), and poorly differentiated (G3) endometrial carcinoma for immunohistochemical
study. The tissues were fixed in formalin and embedded in paraffin. Sections were taken from the paraffin-embedded tissue and stained
with 1:200 anti-EGFR or 1:150 anti-HER-2. Primary antibody binding was detected through a biotin-conjugated secondary antibody. Top
panels, HE stained; upper middle panels, stained with anti-EGFR; lower middle panels, stained with anti-HER-2; bottom panels, negative control.
Magnification × 200. ars =1000 μm. b The expression status of EGFR and HER-2 in each grade of tumor were assessed by immunohistochemistry.
The ratio of immunopositive cases for each protein is represented in the bars graph. c The carcinoma portions were excised, and RNA was isolated.
EGFR and HER-2 mRNA levels were measured using quantitative RT-PCR. GAPDH mRNA levels were quantitated as an internal control. The amounts of
EGFR and HER-2 mRNA were respectively normalized by the amounts of GAPDH mRNA. *, Decrease in the expression level of EGFR mRNA in
G3 compared to those in G1 and G2 cancers, P < 0.05
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blotting, quantitative RT-PCR, and growth inhibition
assay.
Growth inhibition assay
Cells were plated at a concentrations of 5000 cells
(Ishikawa, KLE) or 10,000 cells (HEC-1A) per well in
96-well plates. After 12 h incubation at 37 °C in a humidi-
fied atmosphere containing 5 % CO2, the cells were
treated with the pharmacological compounds (ErbB in-
hibitor: erlotinib [EGFR tyrosine kinase inhibitor) and
trastuzumab [HER-2 monoclonal antibody]) or transfected
with siRNA, and incubated for further 48 h in the same
conditions. Erlotinib was dissolved in DMSO and added
to the cell culture medium at a concentration not exceed-
ing 0.1 % (v/v). At the end of various treatments, 10 μL
cell counting solution (WST-1, Dojindo Labs, Tokyo,
Japan) was added. Cells were incubated for 1 h and the
absorbance was measured at a wavelength of 450–650 nm
using a Microtiter Plate Reader (Becton Dickinson,
Franklin Lakes, NJ, USA).
Tumor xenograft model and treatment
All procedures involving animals followed ethical princi-
ples according the NIH Guide for Care and Use of the
Laboratory Animals and were approved by the Gunma
University Animal Care and Use Committee (Permit
Number: 13–042). Female mice, 4-weeks-old nude BALB/
C nu/nu, were obtained from Charles River Japan (Tokyo,
Japan). Mice were housed in suitable cages in a pathogen-
free condition in a room maintained at 23–26 °C, 50 % hu-
midity, and 12-h light/12-h dark cycle. The mice were
allowed to acclimatize for 2 weeks prior to the study. Regu-
lar health checks were performed. Mice were implanted
with tumor cells at a single subcutaneous (s.c.) site on the
shoulder flank (5 × 105 HEC-1 and 1 × 106 Ishikawa per
mouse in a 0.1 mL growth factor reduced matrigel (Corn-
ing, Tewksbury, MA, USA) and 0.1 mL culture medium.
Tumor-bearing mice were randomized into erlotinib (1 mg,
3 mg, 10 mg, 30 mg/kg/day, intraperitoneal (i.p.) for 5 days
per week), pertuzumab (1 mg, 3 mg, 10 mg/kg, i.p. twice
per week), and vehicle (DMSO and distilled water, i.p.)
Fig. 2 EGFR and HER-2 protein and mRNA expression levels in EC cell lines. a Cells were cultured, harvested, solubilized in detergent, and resolved
by 12 % reducing SDS-PAGE. Each sample was confirmed with anti-EGFR, anti-HER-2, and anti-β-actin antibody. The detection of β-actin protein
served as a loading control. The blot is representative of three independent experiments. *, increased expression levels of EGFR protein in HEC-1A
compared to those in HEC293 and Ishikawa, P < 0.001 **, increased expression levels of EGFR protein in HEC-1A compared to those in KLE,
and increased expression levels of HER-2 protein in Ishikawa and KLE compared to those in HEC-1A, P < 0.05. b EGFR and HER-2 mRNA levels
were measured by quantitative RT-PCR. Data were normalized with GAPDH mRNA levels in each sample. Data represent the means ± SEMs of
five independent experiments. *, increased expression levels of EGFR mRNA in HEC-1A compared to those in HEC293 and Ishikawa, P< 0.005 **, increased
expression level of EGFR mRNA in HEC-1A compared to those in KLE, and increased expression level of HER-2 mRNA in Ishikawa and KLE compared to
those in HEC-1A, P< 0.05
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groups when the mean tumor volume was 100–150 mm3.
Equal volume of the vehicle (0.1 mL) was injected in all
animals. Tumor volume and body weight were determined
twice weekly. The tumor volume was determined accord-
ing to the following formula: tumor volume = (length) x
(width)2/2. On day 28, mice were euthanized; tumor was
excised, and fixed in formalin. Tumors were processed for
hematoxylin and eosin (HE) staining.
Data analysis
The data represent the mean ± standard error of the mean
(SEM) from at least three independent experiments.
Comparisons between groups were performed by one-
way ANOVA or chi-square test. The significance of the
differences between the mean values of the control group
and each treated group was determined by Dunnett’s
multiple-comparison test. These analyses were 2-tailed
tests, and a value of P < 0.05 was considered significant.
The cumulative survival curve was estimated by the
Kaplan-Meier method. All analyses were performed with
IBM SPSS statistics 21 software.
Results
Expression of EGFR and HER-2 in endometrial cancer
Fifty-one surgically resected endometrioid carcinoma sam-
ples, classified as: well (Grade 1, G1), moderately (G2), or
poorly (G3) differentiated adenocarcinoma, were obtained
from patients who had undergone surgery at Gunma
University Hospital (Table 1). In our institution, 20.9 %
of patients with endometrial cancer with low-grade
endometrioid histology were diagnosed as stage III and
IV. As a first step, IHC was carried out on endometrial
carcinoma to confirm the expression of EGFR and HER-2
proteins (Fig. 1a and b). EGFR protein was highly expressed
in G1 and G2 endometrioid carcinoma (p = 0.014, χ2
(2) = 8.6) whereas HER-2 was almost evenly expressed
in G1, G2, and G3 tumors (P = 0.52, χ2 (2) = 1.5). We
also evaluated EGFR and HER-2 mRNA expression
levels in EC tissues by RT-PCR (Fig. 1c). EGFR mRNA
levels were higher in G1 and G2 (P < 0.05) than in G3,
but there was no significant difference in HER-2 mRNA
expression between the three grades.
We did further Kaplan-Meier analysis of survival with
patients who expressed or not EGFR by IHC. No signifi-
cant differences were found between the two groups for
overall survival (data not shown).
EC cell line experiments
Cancer cell lines were utilized for further experiments to
elucidate the roles of EGFR and HER-2 in EC cells.
Three cell lines (Ishikawa, HEC-1A, and KLE) were evalu-
ated by western blotting to determine protein expression
Fig. 3 Phosphorylation of ERK treated EGF in EC cell lines. EC cells were incubated with epithelial growth factor (EGF) (1–1000 pg/mL), and cells
were harvested at the 10 min for western blotting. Each sample was confirmed with either anti-phospho-ERK or anti-total-ERK
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levels of EGFR and HER-2. HEC-1A showed high EGFR
and low HER-2 expression, while Ishikawa had low EGFR
and high HER-2 expression. In KLE, the expression levels
of EGFR and HER-2 were intermediate between Ishikawa
and HEC-1A (Fig. 2a). These results were reconfirmed by
quantitative RT-PCR experiments, which indicated that
EGFR mRNA levels were significantly the highest in HEC-
1A (P < 0.005), and HER-2 mRNA levels were highly
expressed in Ishikawa (P < 0.05) (Fig. 2b).
The three cell lines were treated with EGF and were
evaluated for downstream signaling of EGFR, by detect-
ing phosphorylated ERK 1/2 by western blotting (Fig. 3).
The phosphorylation of ERK 1/2 was found to be in-
duced in all three cell lines, but in HEC-1A, the increase
occurred at a lower concentration compared to the other
two cell lines. This result suggested that the amount
of EGFR expression was an important factor for the
activation of mitotic-activated protein kinase (MAPK)
pathway by EGF stimulation in endometrial carcinoma
cells.
To investigate the significance of EGFR and HER-2 in
the proliferation of endometrial cancer cells, all cells were
transfected with siRNA to knock down EGFR or HER-2.
After 48 h, EGF was added, and ERK 1/2 phosphorylation
and proliferation were evaluated. When EGFR was
knocked down (Fig. 4a and c), all cells showed decreased
ERK 1/2 phosphorylation (P < 0.05). The viability of Ishi-
kawa cells was reduced to 72 %, HEC-1A to 57 %, and
KLE to 64 %, compared to the negative control (P < 0.05).
When HER-2 was knocked down (Fig. 4b and c), ERK 1/2
phosphorylation was significantly decreased in Ishikawa,
which highly expressed HER-2 (P < 0.05), but not in HEC-
1A and KLE. Similarly, cell viability was reduced in Ishi-
kawa (to 65 % compared with negative control) (P < 0.05),
but not in other cell types (HEC-1A: to 94 % KLE: to 93 %
compared with negative control).
Fig. 4 EGFR is involved in ERK phosphorylation in EC cell lines. All EC cells were transfected with 10 nM of siRNA (control, EGFR, or HER-2). Cells
were harvested 48 h after transfection to evaluate ERK phosphorylation after knockdown of EGFR (a) or HER-2 protein (b). Cells were incubated
with EGF (1 ng/mL) for 10 min and harvested for western blot analysis. The detection of β-actin protein served as a loading control. The
blot is representative of three independent experiments. The expression levels of phosphorylated ERK were quantified by scanning the digital image
and digitized data were analyzed with the Image J. Data represent the means ± SEMs of three independent experiments. *, decreased compared to
siRNA control transfection (NC), P < 0.05. c All EC cells were transfected with 10 nM of siRNA (control, EGFR or HER-2), and cell proliferation
was monitored after 48 h using WST-1 assay. *, increased compared to no treatment cell, P < 0.05.**, decreased compared to siRNA control
transfection (Negative Control), P < 0.05
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Growth inhibition assay following ErbB inhibitor
treatment in vitro
The results in Fig. 4 prompted us to investigate whether
ErbB inhibitors could effectively inhibit EC proliferation.
In subsequent experiments, all cells were treated with
erlotinib (ERL: EGFR tyrosine kinase inhibitor) or
trastuzumab (TRA: HER-2 monoclonal antibody), and
evaluated for ERK 1/2 phosphorylation and prolifera-
tion in EC cells. All cells treated with ERL showed de-
creased ERK 1/2 phosphorylation (P < 0.001) (Fig. 5a)
and reduction in cell viability. However, ERL had a
most pronounced effect to HEC-1A compared with
Ishikawa and KLE in cell viability (HEC-1A 38 %, Ishikawa
78 %, and KLE 72 %, respectively) (Fig. 5b). In the case of
TRA treatment (Fig. 5a and b), only Ishikawa cells
showed a decrease in ERK 1/2 phosphorylation (P < 0.05)
and cell viability to 78 % compared with vehicle control
(P < 0.05).
Tumor growth inhibition assay following ErbB inhibitor
treatment in mice xenograft model
Because the in vitro studies were examined for short pe-
riods, the long-term effect of either ERL or TRA was stud-
ied using an EC xenograft in vivo model. Tumor-bearing
mice were treated with either ERL or TRA for 28 days. The
results showed that only tumors in HEC-1A xenografted
mice treated with ERL at a dose of 3 mg/kg or more (Fig. 6a
and b) were reduced, whereas TRA did not induce signifi-
cant tumor growth inhibition in mice implanted with either
HEC-1A or Ishikawa. The resected tumor from the xeno-
graft model stained with HE, suggested that clear fibrosis
occurred in HEC-1A tumor treated with ERL (Fig. 6c).
Discussion
In the present study, we demonstrate that both EGFR
mRNA and EGFR protein were highly expressed in
low-grade endometrioid carcinoma, but the expression
Fig. 5 Effect of ERK phosphorylation by erlotinib or trastuzumab on proliferation in EC cell lines. a All cells were treated with either ERL (3 μM,
30 μM) or TRA (100 μg/mL, 1000 μg/mL). After a 2-h incubation with the drug, cells were treated EGF (1 ng/mL) for 10 min and harvested for
western blot analysis. The blot is representative of three independent experiments. The expression levels of phosphorylated ERK were quantified
by scanning the digital image and digitized data were analyzed with the Image J. Data represent the means ± SEMs of three independent
experiments. *, decreased with the drug treatment compared to control, P < 0.001. b All cells were treated with either ERL (0.1–30 μM) or
TRA (10–1000 μg/mL). After 2 h incubation with the drug, all cells were treated EGF (1 ng/mL). Cell proliferation was monitored after 96 h
using WST-1 assay. *, decreased as compared to vehicle control, P < 0.01
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was low in high-grade endometrioid carcinoma. We
examined the molecular factors that underlie the variable
responsiveness to erlotinib in accordance with the expres-
sion levels of both EGFR mRNA and EGFR protein in the
endometrial carcinoma cells, using quantitative RT-PCR
and IHC. We found that erlotinib, a known potent select-
ive inhibitor of the EGFR tyrosine kinase, significantly in-
hibits the proliferation of endometrial carcinoma cells,
which express high levels of EGFR in xenograft mice
models.
The degree of tumor differentiation is one of the prog-
nostic factors in EC; low-grade endometrioid tumors tend
not to progress to deep myometrial invasion or spread to
distant sites [35]. In contrast, high-grade endometrioid
tumor is aggressive and diagnosed at advanced stages, it
involves recurrent or metastatic tumors at high rate. On
the other hand, overall prognosis for those who are diag-
nosed with low-grade tumor is positive, although the
number of patients with recurrent or metastatic tumors is
still large due to the corresponding amount of newly diag-
nosed type I EC patients [3, 4]. In fact, in our institution,
20.9 % of endometrial cancer patients with low-grade
endometrioid histology have been diagnosed as stage III
and IV (Table 1). We comprehensively analyzed EGFR
and HER2 expression levels in endometrioid carcinoma
(Fig. 1), demonstrating that EGFR mRNA and protein
were highly expressed in low-grade endometrioid tumor
compared to high-grade endometrioid tumor. In contrast,
HER2 was not significantly expressed at a varying level
in any grade of endometrioid tumor. EGFR mediates
the activation of intracellular signaling pathways, such
as MAPK-ERK and PI3K-AKT pathways, resulting in
enhanced proliferation and cell survival in EC cells.
Collectively, these results prompted us to further inves-
tigate the significance of EGFR in the proliferation of
low-grade endometrioid tumor.
To date, anti-EGFR antibody, anti-EGFR, or dual EGFR/
HER2 tyrosine kinase inhibitors have been evaluated across
a variety of disease types. For HER2-positive patients with
breast cancer, trastuzumab has significantly reduced the
rate of recurrence [36]. In the subsequent study [37], lapati-
nib, the EGFR and HER2 dual kinase inhibitor, displayed
significant antiproliferative effects in HER2 overexpressing
breast tumor cell lines, suggesting that the EGFR expres-
sion level has no association with the sensitivity to lapatinib.
In contrast, both EGFR and HER2 expression has been
found in patients with non-small-cell lung cancer with poor
prognosis [38], erlotinib was beneficial in those patients in
an EGFR-dependent way [39]. In this study, we confirmed
that the amount of EGFR expression plays an important
Fig. 6 Inhibition of tumor growth by erlotinib (ERL) in vivo. Mice were implanted with Ishikawa (a) or HEC-1A (b) and treated with ERL or TRA for
28 days. Tumor volume was measured twice a week. Data represent the means ± SEMs of three independent tumor volumes. *, decreased as
compared to vehicle control, P < 0.05. c On day 28 after starting treatment, mice were euthanized and tumor was excised. The tissues were fixed
in formalin and embedded in paraffin. Sections were taken from the paraffin-embedded tissue and HE stained. Top and upper middle panels,
Ishikawa tumor; lower middle and bottom panels, HEC-1A tumor. Magnification × 200.Bars =1000 μm
Nishimura et al. BMC Cancer  (2015) 15:957 Page 9 of 11
role in MAPK pathway in endometrial cancer cell (Fig. 3),
suggesting that endometrial cancer with highly expressed
EGFR is strongly effected by anti-EGFR drugs. Further-
more, the antitumor effects of erlotinib against HEC-1A
cells clearly inhibited tumor growth both in vitro (Fig. 5b)
and in vivo (Fig. 6b). On the other hand, trastuzumab did
not reduce the tumor growth of Ishikawa cells in xenograft
mice (Fig. 6a). Taken together, the current data indicate that
the expression levels of EGFR is a key factor in the molecu-
lar targeted therapy against pathogenic tyrosine kinases in
endometrial cancer, and suggest that EGFR inhibitors may
be clinically useful for well-defined subgroups of endomet-
rial cancer patients with highly-expressed EGFR.
A phase II study (NCIC IND-148) has been largely
considered to have concluded that erlotinib is not a
promising agent for recurrent or metastatic EC. How-
ever, in that study, tumors were regarded as EGFR posi-
tive if tumor cell membranes stained positively with
anti-EGFR antibody in IHC in more than 10 % of
tumor cells. Thus, we speculate that this clinical study
contained large cases of high-grade endometrioid tumors
and type II EC, based on our finding that a majority of cell
membranes were stained in low-grade endometrioid
tumors (Fig. 1).
Patients with risk factors such as tumor grade, deep
myometrial invasion, and positive lymph nodes are rec-
ommended for systemic chemotherapy, although it is
not unanimously accepted. Basic cancer research is con-
ducted to identify the markers that determine patients
to chemotherapy regimen according to the responses. In
malignant tumors, it is unlikely that one signaling path-
way is solely engaged in its aggressive behavior including
progression and metastasis. However, the present data
demonstrate that erlotinib has efficacy in the treatment
of endometrial cancers, which highly express EGFR. We
believe that further analysis of the molecular signature
of the EC tumors will define patients who can be bene-
fited by erlotinib therapy.
Conclusions
Type I EC accounting for 80 % of EC is associated with
better clinical outcome than type II EC. However, a sub-
stantial number of patients have to deal with recurrent
tumors due to corresponding amounts of type I EC pa-
tients. In this study, we found that EGFR protein was
highly expressed in low grade endometrioid carcinoma
tissue and that the proliferation of an EC cell line with
high EGFR expression was attenuated by erlotinib, an
EGFR tyrosine kinase inhibitor. In tumor xenograft mouse
models, erlotinib clearly reduced the growth of tumors
with high levels of EGFR expression. This agent could be
further developed for pre-clinical and clinical studies
specific patient subgroups in advanced stage or recurrent
EC with high-EGFR expressed tumors.
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